Moleculin Stock Buy Hold or Sell Recommendation

MBRX
 Stock
  

USD 1.47  0.02  1.38%   

Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Moleculin Biotech CS is 'Buy'. Macroaxis provides Moleculin Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MBRX positions. The advice algorithm takes into account all of Moleculin Biotech's available fundamental, technical, and predictive indicators you will find on this site.
  
Refresh
The advice is provided from Moleculin Biotech's buy-and-hold perspective. Additionally, see Moleculin Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Moleculin and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Moleculin Biotech CS.

Execute Moleculin Biotech Buy or Sell Advice

The Moleculin recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Moleculin Biotech CS. Macroaxis does not own or have any residual interests in Moleculin Biotech CS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Moleculin Biotech's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Moleculin BiotechBuy Moleculin Biotech
Buy

Volatility

Moderately volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Close to AverageDetails

Economic Sensitivity

Almost mirrors the marketDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

Very WeakDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Moleculin Biotech CS has a Risk Adjusted Performance of (0.046495), Jensen Alpha of 0.0389, Total Risk Alpha of 0.3703 and Treynor Ratio of (0.15)
We provide investment recommendation to complement the last-minute expert consensus on Moleculin Biotech CS. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Moleculin Biotech is not overpriced, please verify all Moleculin Biotech CS fundamentals, including its net income, as well as the relationship between the book value per share and market capitalization . Please also check out Moleculin Biotech price to earning to check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Moleculin Biotech Trading Alerts and Improvement Suggestions

Moleculin Biotech generated a negative expected return over the last 90 days
Moleculin Biotech may become a speculative penny stock
Moleculin Biotech has high historical volatility and very poor performance
Net Loss for the year was (15.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Moleculin Biotech CS currently holds about 70.9 M in cash with (18.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Moleculin Biotech has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Yan Joy of 15000 shares of Moleculin Biotech subject to Rule 16b-3

Moleculin Biotech current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moleculin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moleculin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price12.39
Target Median Price9.50
Target High Price29.00
Recommendation Mean1.70
Number Of Analyst Opinions4
Target Low Price1.57
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Moleculin Biotech Returns Distribution Density

The distribution of Moleculin Biotech's historical returns is an attempt to chart the future uncertainty of Moleculin Biotech's future price movements. The chart of the probability distribution of Moleculin Biotech stock daily returns describes the distribution of returns around its average expected value. We use Moleculin Biotech CS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Moleculin Biotech returns is essential to provide solid investment advice for Moleculin Biotech stock.
Mean Return-0.14Value At Risk-7.58
Potential Upside5.04Standard Deviation3.89
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Moleculin Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Moleculin Biotech Cash Flow Accounts

201720182019202020212022 (projected)
Capital Expenditure(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Depreciation Amortization and Accretion18 K68 K199 K200 K164 K135.33 K
Net Cash Flow or Change in Cash and Cash Equivalents2.71 M(580 K)3.6 M4.44 M55.73 M60.13 M
Issuance Purchase of Equity Shares10.06 M12.04 M20.85 M22.57 M74.75 M80.65 M
Net Cash Flow from Financing10.06 M12.04 M20.85 M22.55 M74.72 M80.62 M
Net Cash Flow from Investing(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Net Cash Flow from Operations(7.32 M)(12.2 M)(17.2 M)(17.77 M)(18.95 M)(19.45 M)
Share Based Compensation707 K1.14 M1.54 M1.68 M2.37 M2 M

Moleculin Biotech Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Moleculin Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Moleculin Biotech stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Moleculin stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.038869
β
Beta against DOW1.01
σ
Overall volatility
3.90
Ir
Information ratio 0.0095

Moleculin Biotech Volatility Alert

Moleculin Biotech CS exhibits very low volatility with skewness of -0.26 and kurtosis of 1.84. However, we advise investors to further study Moleculin Biotech CS technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Moleculin Biotech's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Moleculin Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Moleculin Biotech Implied Volatility

Moleculin Biotech's implied volatility exposes the market's sentiment of Moleculin Biotech CS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moleculin Biotech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moleculin Biotech stock will not fluctuate a lot when Moleculin Biotech's options are near their expiration.

Moleculin Biotech Fundamentals Vs Peers

Comparing Moleculin Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Moleculin Biotech's direct or indirect competition across all of the common fundamentals between Moleculin Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Moleculin Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Moleculin Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Moleculin Biotech to competition
FundamentalsMoleculin BiotechPeer Average
Return On Equity(32.85) %(0.31) %
Return On Asset(25.38) %(0.14) %
Current Valuation(25.3 M)16.62 B
Shares Outstanding28.58 M571.82 M
Shares Owned by Insiders2.15 %10.09 %
Shares Owned by Institutions14.67 %39.21 %
Number of Shares Shorted301.02 K4.71 M
Price to Earning(3.81) X28.72 X
Price to Book0.52 X9.51 X
Price to Sales0.83 X11.42 X
EBITDA(22.8 M)3.9 B
Net Income(15.89 M)570.98 M
Cash and Equivalents70.9 M2.7 B
Cash per Share2.48 X5.01 X
Total Debt159 K5.32 B
Debt to Equity0.002 %48.70 %
Current Ratio20.02 X2.16 X
Book Value Per Share2.84 X1.93 K
Cash Flow from Operations(18.95 M)971.22 M
Short Ratio2.87 X4.00 X
Earnings Per Share(0.70) X3.12 X
Number of Employees1318.84 K
Beta1.9-0.15
Market Capitalization42.01 M19.03 B
Total Asset28.09 K29.47 B
Retained Earnings(40.6 M)9.33 B
Working Capital(744.7 K)1.48 B
Current Asset28.09 K9.34 B
Current Liabilities772.79 K7.9 B
   Acquisition by Yan Joy of 15000 shares of Moleculin Biotech subject to Rule 16b-3 [view details]

About Moleculin Biotech Buy or Sell Advice

When is the right time to buy or sell Moleculin Biotech CS? Buying financial instruments such as Moleculin Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Moleculin Biotech investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2021 2022 (projected)
Accounts Payable1.36 M1.2 M
Receivables23 K24.82 K

Use Investing Ideas to Build Portfolios

In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Silver Thematic Idea Now

Silver
Silver Theme
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 30 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
View All  Next Launch Silver
Additionally, see Moleculin Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
42 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.